Skip to content

Study · Not a test of the peptide alone · 2019

2 results

Alzheimer's disease-associated (hydroxy)methylomic changes in the brain and blood.

Lardenoije R, Roubroeks JAY, Pishva E, Leber M, Wagner H, Iatrou A, Smith AR, Smith RG, Eijssen LMT, Kleineidam L, Kawalia A, Hoffmann P and 17 more

Show all authors

Luck T, Riedel-Heller S, Jessen F, Maier W, Wagner M, Hurlemann R, Kenis G, Ali M, Del Sol A, Mastroeni D, Delvaux E, Coleman PD, Mill J, Rutten BPF, Lunnon K, Ramirez A, van den Hove DLA

Clinical epigenetics27 Nov 2019Cited by 116 (Europe PMC)

PMID31775875 (opens in a new tab)PMCIDPMC6880587 (opens in a new tab)DOI10.1186/s13148-019-0755-5 (opens in a new tab)PepBankPUB-31775875
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundLate-onset Alzheimer's disease (AD) is a complex multifactorial affliction, the pathogenesis of which is thought to involve gene-environment interactions that might be captured in the epigenome. The present study investigated epigenome-wide patterns of DNA methylation (5-methylcytosine, 5mC) and hydroxymethylation (5-hydroxymethylcytosine, 5hmC), as well as the abundance of unmodified cytosine (UC), in relation to AD.ResultsWe identified epigenetic differences in AD patients (n = 45) as compared to age-matched controls (n = 35) in the middle temporal gyrus, pertaining to genomic regions close to or overlapping with genes such as OXT (- 3.76% 5mC, pŠidák = 1.07E-06), CHRNB1 (+ 1.46% 5hmC, pŠidák = 4.01E-04), RHBDF2 (- 3.45% UC, pŠidák = 4.85E-06), and C3 (- 1.20% UC, pŠidák = 1.57E-03). In parallel, in an independent cohort, we compared the blood methylome of converters to AD dementia (n = 54) and non-converters (n = 42), at a preclinical stage. DNA methylation in the same region of the OXT promoter as found in the brain was found to be associated with subsequent conversion to AD dementia in the blood of elderly, non-demented individuals (+ 3.43% 5mC, pŠidák = 7.14E-04).ConclusionsThe implication of genome-wide significant differential methylation of OXT, encoding oxytocin, in two independent cohorts indicates it is a promising target for future studies on early biomarkers and novel therapeutic strategies in AD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01HumanNot a test of Oxytocin aloneObservational studyOther

    In blood of non-demented elderly people, higher 5mC methylation in the OXT promoter was linked to later conversion to Alzheimer's dementia.

    In plain wordsIn older people without dementia, more methylation near the oxytocin gene in blood was linked to later Alzheimer's dementia; oxytocin levels were not measured.

    Peptide
    Oxytocin
    Outcome
    IncreaseOXT promoter 5mC methylation in blood and later conversion to AD dementia
    Study

    n = 96

    Comparator
    Non-converters
    Outcome group
    Aging markers · Nervous system and cognition

    Measurements

    5mC difference
    3.43%
    OXT promoter, converters versus non-converters

    Source sentences

    Summary
    DNA methylation in the same region of the OXT promoter as found in the brain was found to be associated with subsequent conversion to AD dementia in the blood of elderly, non-demented individuals (+ 3.43% 5mC, pŠidák = 7.14E-04).
    1 context sentence
    Summary · context
    In parallel, in an independent cohort, we compared the blood methylome of converters to AD dementia (n = 54) and non-converters (n = 42), at a preclinical stage.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 02HumanNot a test of Oxytocin aloneObservational studyOther

    In the middle temporal gyrus, Alzheimer's disease patients had 3.76 percentage points lower 5mC methylation near the OXT gene than age-matched controls.

    In plain wordsIn brain tissue, people with Alzheimer's disease had less DNA methylation near the oxytocin gene than matched controls; oxytocin levels were not measured.

    Peptide
    Oxytocin
    Outcome
    DecreaseOXT gene 5mC methylation in middle temporal gyrus
    Study

    n = 80

    Comparator
    Age-matched controls
    Outcome group
    Aging markers · Nervous system and cognition

    Measurements

    5mC difference
    −3.76%
    OXT, AD versus controls

    Source sentences

    Summary
    We identified epigenetic differences in AD patients (n = 45) as compared to age-matched controls (n = 35) in the middle temporal gyrus, pertaining to genomic regions close to or overlapping with genes such as OXT (- 3.76% 5mC, pŠidák = 1.07E-06)

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.